CUTX-101 is a small molecule commercialized by Fortress Biotech, with a leading Phase III program in Menkes Disease (Kinky Hair Disease). According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of CUTX-101’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for CUTX-101 is expected to reach an annual total of $19 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

CUTX-101 Overview

CUTX-101 (Copper histidinate) is under development for the treatment of Menkes disease. The drug candidate is administered through subcutaneous route. Copper histidine acts as a replacement therapy.

Fortress Biotech Overview

Fortress Biotech, formerly Coronado Biosciences, identifies, acquires, develops and commercializes marketed pharmaceuticals and development-stage pharmaceutical product candidates. The company provides business, scientific, regulatory, and legal support for advancing the products or product candidates of its partner firms. It is a marketing partner for various branded drugs indicated for the treatment of radiation dermatitis, severe acne, athlete’s foot, inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and other skin infections. Fortress Biotech is headquartered in Florida, the US.
The company reported revenues of (US Dollars) US$84.5 million for the fiscal year ended December 2023 (FY2023), an increase of 11.6% over FY2022. The operating loss of the company was US$145.7 million in FY2023, compared to an operating loss of US$203.6 million in FY2022. The net loss of the company was US$60.6 million in FY2023, compared to a net loss of US$86.6 million in FY2022.

For a complete picture of CUTX-101’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.